Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD5024 1% in Acne Vulgaris
NCT03034460Phase 2Completed
- Sponsor
- Galderma
- Start
- Apr 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, single-blind trial of ivermectin in acne vulgaris (4 arms), sponsored by Galderma. Primary endpoint: Inflammatory Lesion Count (Papules and Pustules) at Day 40. Started Apr 2016; status: completed.
02
Drugs
ivermectin
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT03034460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03034460.